Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATH BRIGHTE appendix continued access study of Rukobia for HIV infection
2025-522910-21-00Phase 3Authorised
- Sponsor
- ViiV Healthcare
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of fostemsavir in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoints: Reasons for discontinuation of study intervention, Incidence and outcome of serious adverse events and 1 more. Planned start Oct 2026; status: authorised.
02
Drugs
fostemsavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2025-522910-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522910-21-00.